There have been claims that COVID-19 oral antivirals, such as molnupiravir and Paxlovid (nirmatrelvir + ritonavir; Pfizer), will “change the course of the pandemic”. But with limited supply, a short treatment window and only a few patient groups eligible to receive them — can these drugs really turn things around?
In this episode of The PJ Pod, Dawn Connelly, features editor, and Julia Robinson, clinical and science editor, look at how these novel drugs work and answer questions from PJ readers on how they will be used in practice.
To explain all this, our editors are joined by Penny Ward, visiting professor in pharmaceutical medicine at King’s College London, and Fiona Marra, a consultant infectious disease pharmacist based in Scotland, who has a central role in deploying the COVID-19 antivirals.
Thank you to Rob Ardley, Nicola Vasey, Umeh Ali and Gareth Malson for their questions. This episode was produced by Geoff Marsh.
Want to hear more from The PJ Pod? Follow us on Spotify, Google Podcasts, Apple Podcasts or Soundcloud to download our latest podcasts.
